Continuing Medical Education

Earn up to 27 AMA PRA Category 1 Credits™. Eligible physicians may also claim up to 6.75 ABIM MOC Points. 

Continuing Medical Education

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. 
The Endocrine Society designates this activity for a maximum of 27 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Please note that while other accrediting bodies accept AMA PRA Category 1 Credit™, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body. 

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.75 Maintenance of Certification (MOC) points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 


  • November 21, 2024: credit claim expiration 
  • December 31, 2024: access to CEU online platform expires for non-members registered attendees. 
  • December 31, 2025: access to CEU Recordings expires for registered member attendees 

Credit Claim Instructions

For AMA PRA Category 1 Credits™, ABIM MOC Points: 1
1. Visit
2. Select "My Courses" or the Home icon on the left-hand side
3. Search for and click on Clinical Endocrinology Update 2024
4. Complete the evaluation
5. Claim credit commensurate with your participation



The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available. 


When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications. 


The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events. 


The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties. 

Event Information

Clinical Endocrinology Update (CEU) 2024
September 19-21, 2024
Online Event

Important Dates

Registration Opens:
April 23, 2024

Early Registration Deadline:
August 5, 2024

Credit Claiming Deadline: 
November 21, 2024

Final Day to Access Virtual Platform: 
November 21, 2024